Literature DB >> 23493936

In vitro determination of the antibiotic susceptibility of biofilm-forming Pseudomonas aeruginosa and Staphylococcus aureus: possible role of proteolytic activity and membrane lipopolysaccharide.

Majed M Masadeh1, Nizar M Mhaidat, Karem H Alzoubi, Emad I Hussein, Esra'a I Al-Trad.   

Abstract

We carried out a comprehensive overview of inhibitory effects of selected antibiotics on planktonic and biofilm cells of Staphylococcus aureus (ATCC 29213) and Pseudomonas aeruginosa (ATCC 27853) strains. The possible involvement of protease activity and the lipopolysaccharide (LPS) profile of P. aeruginosa were also analyzed. Biofilm cells of both strains were more resistant to antibiotics than their planktonic counterparts. Protease activity was increased in both strains in the biofilm forms. Challenge with sublethal doses of antibiotics also increased proteolytic activity of biofilm cells. Additionally, the LPS profile of P. aeruginosa showed pattern alterations of the biofilm that can contribute to biofilm resistance and survival. These observations provide evidence for the involvement of bacterial proteolytic activity and LPS profile in the resistance of biofilm bacteria to antibiotics compared to their planktonic counterparts.

Entities:  

Keywords:  Pseudomonas aeruginosa; Staphylococcus aureus; biofilm; lipopolysaccharide; proteolytic activity

Year:  2013        PMID: 23493936      PMCID: PMC3593709          DOI: 10.2147/IDR.S41501

Source DB:  PubMed          Journal:  Infect Drug Resist        ISSN: 1178-6973            Impact factor:   4.003


Many pathogenic and commensal bacteria are capable of transitioning between lifestyles in the environment and the human host.1 These bacteria must be able to adapt to sudden shifts in availability of nutrients and to primary and secondary host immune defenses.2 One particularly important and clinically relevant example of bacterial adaptation is the ability to grow as biofilms.3–5 Biofilms, a surface-associated bacterial community, are complex and ordered bacterial societies that are capable of growing in connection with different biological or inert surfaces.1 The major clinical consequence of different disease-causing bacteria correlates with the problems of therapeutic killing of attached cells.6 Biofilms are commonly associated with many health problems, such as endocarditis, otitis media, periodontitis, prostatitis, and urinary tract infections.7–10 Several bacteria, such as Escherichia coli, Staphylococcus aureus, Haemophilus influenza, and Pseudomonas aeruginosa, can form biofilms in the body tissues, leading to different infections.10–12 It has been estimated that biofilms account for two-thirds of the bacterial infections that physicians encounter, particularly in immunocompromised patients.13 Antibiotics have been used to treat patients with infectious diseases. They target important bacterial structures and cellular pathways, such as the cell wall, DNA, RNA, protein synthesis machinery, and bacterial metabolism.14 However, uncontrolled or long-term use of antibiotics results in the adaptation and development of resistance leading to treatment failure, prolonged or additional hospitalization, increased costs of care, and increased mortality.11,15 The mechanism of resistance of microbial biofilms to antibiotics is not clear. However, it seems to be multifactorial and may vary from one organism to another.16 In this study we investigated the possible involvement of proteolytic activity and lipopolysaccharides (LPSs) in increased resistance to antibiotics during the biofilm state.

Materials and methods

Bacterial strains and culture

Pseudomonas aeruginosa (ATCC 27853) and S. aureus (ATCC 29213) strains were obtained from the American type culture collection and cultivated on Mueller Hinton agar (Becton Dickinson and Company, Cockeysville, MD, USA) for 24 hours at 37°C under standardized aseptic conditions.

Antimicrobial agents

The following antimicrobial agents were used for susceptibility testing against S. aureus: cefaclor (cephalosporins) at a concentration of (32 μg/mL), amoxicillin (aminoglycosides; 32 μg/mL), cotrimoxazole (sulfonamides/folic acid antagonists; 32 μg/mL), and ciprofloxacin (fluoroquinolones; 0.125 μg/mL). We used amikacin (aminoglycosides, 0.25 μg/mL) and cotrimoxazole (32 μg/mL), ciprofloxacin (0.0625 μg/mL), and ceftazidime (32 μg/mL) (cephalosporins) for susceptibility testing against P. aeruginosa. All antibiotics were used as raw material, and purchased from Sigma-Aldrich, MI, USA.

Bacterial culture

Staphylococcus aureus and P. aeruginosa biofilms were developed as previously described17 under standardized aseptic conditions. Briefly, 100 μL of bacterial suspension from each strain was cultivated in polypropylene tubes containing 2 mL of trypticase soy broth (TSB) supplemented with 1% glucose (Becton Dickinson and Company, Cockeysville, MD, USA) for 48 hours at 37°C. Culture media was refreshed after 24 hours of incubation. After 48 hours of incubation, biofilm cells were harvested by discarding the culture media and washing the tubes three times with phosphate buffer saline (PBS; pH 7.2) to remove nonadherent bacteria; the adhered cells were then harvested by vortex and centrifugation. The pellet was suspended in PBS (pH 7.2) to achieve the desired turbidity (comparable to a McFarland turbidity standard of 0.5). Screening for biofilm formation was achieved as previously described.18 Briefly, after being emptied from their content, culture tubes were stained with trypan blue or safranin. Biofilms were judged by the appearance of a visible film lining the walls of the tube. Observations were carried out by three independent observers. Biofilms were scored as absent (score 0), weak (score 1), moderate (score 2), or strong (score 3). Average scores were used.

Determination of minimum inhibitory concentrations (MICs) of antibiotics for planktonic and biofilm cells

The MIC values of both S. aureus and P. aeruginosa planktonic and biofilm cells were tested against selected antibiotics. MICs were determined by using the broth macrodilution method.19 Briefly, 100 μL of adjusted bacterial suspensions equivalent to a 0.5 McFarland standard were added to a twofold serial dilution of selected antibiotics diluted in Mueller Hinton broth. The results were observed after 24 hours of incubation at 37°C. The lowest concentration of antibiotic needed to inhibit microbial growth compared to the control culture was defined as the MIC. Tests were performed in triplicate for each antibiotic.

Influence of sub-MICs of selected antibiotics on biofilm cells

To determine the effects of sub-MICs of antibiotics on S. aureus and P. aeruginosa biofilms, 100 μL of a bacterial biofilm suspension was added to TSB (supplemented with 1% glucose) containing sub-MICs of each antibiotic (for S. aureus: ciprofloxacin 32 μg/ml, cotrimoxazole 32 μg/ml, cefaclor 32 μg/ml, amoxicillin 32 μg/ml; and for P. aeruginosa: ciprofloxacin 8 μg/ml, amikacin 0.003 μg/ml, ceftazidime 32 μg/ml), and the suspension + antibiotic was then incubated at 37°C for 24 hours. After incubation, the antibiotics were removed by washing the tubes three times, and the cells were pelleted for further investigation.

Proteolytic activity assay

Total protease activity of S. aureus and P. aeruginosa in planktonic and biofilm cells was determined by the azocasein assay.20 Briefly, media from each bacterial strain (30 mL) was added to 50 mL azocasein substrate (2% azocasein (Sigma-Aldrich, MI, USA) in 10 mM Tris HCl, 8 mM CaCl2, pH 7.4). The reaction mixture was incubated for 20 hours. Thereafter, 240 mL 10% trichloroacetic acid was added, and the samples were mixed and allowed to stand for 15 minutes to ensure complete precipitation of undigested material. Tubes were centrifuged at 10,600 xg for 10 minutes, and 240 mL of the supernatant was transferred to tubes containing 280 mL 1.0 M NaOH. The absorbance at 440 nm was determined against a blank tube. One unit of enzyme activity corresponds to the absorbance at maximal digestion of 1 mg azocasein/hour.21 The protease activity was expressed as units/106 bacteria/hour.20

LPS extraction and analysis

We followed the LPS extraction kit guidelines (Intron Biotechnology, Kyungki-Do, Republic of Korea) to extract LPSs from P. aeruginosa planktonic and biofilm cells and biofilms induced with sub-MICs of antibiotics. The LPS profile was then determined using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE) comprising a 4% stacking gel and a 12% separation gel.22 The LPS gel was then fixed and stained according to the method of Tsai and Frasch.23

Statistical analysis

Analysis was performed using GraphPad Prism software (version 4.0; GraphPad Software, Inc, La Jolla, CA). One-way analyses of variance followed by Dunnett’s post hoc test were used to determine any statistically significant difference. A P-value < 0.05 was considered significant.

Results

The MIC values of selected antibiotics against S. aureus and P. aeruginosa biofilm and planktonic cells were determined (Tables S1 and S2). The MIC values of biofilms were generally higher than their planktonic counterparts. We determined protease activity of S. aureus and P. aeruginosa in order to evaluate the possible involvement of proteolytic activity in the resistance of the biofilm form of bacteria (Tables 1 and 2). Results demonstrated that control biofilm had significantly higher proteolytic activity than its planktonic counterpart. When biofilms cells were exposed to sub-MICs of selected antibiotics, most showed a slight but not significant increase in their proteolytic activity.
Table 1

Protease activity of Staphylococcus aureus cells

SamplesProteolytic activity (units/106 bacteria/hour)
Planktonic2.00 ± 0.33
Biofilm3.34 ± 0.55*
Biofilm treated with (1/4) MIC of ciprofloxacin2.44 ± 0.40
Biofilm treated with (1/32) MIC of cefaclor2.88 ± 0.43
Biofilm treated with (1/8 ) MIC of cotrimoxazole3.56 ± 0.65*
Biofilm treated with (1/16) MIC of amoxicillin6.44 ± 0.57*

Notes: n = 4 experiments.

indicates significant difference from the planktonic group at P < 0.05.

Abbreviation: MIC, minimum inhibitory concentration.

Table 2

Protease activity of Pseudomonas aeruginosa cells

SamplesProteolytic activity (units/106 bacteria/hour)
Planktonic2.89 ± 0.47
Biofilm4.44 ± 0.38*
Biofilm treated with (1/8) MIC of ciprofloxacin5.33 ± 0.46*
Biofilm treated with (1/8) MIC amikacin5.78 ± 0.61*
Biofilm treated with (1/8) MIC ceftazidime5.10 ± 0.44*

Notes: n = 4 experiments.

indicates significant difference from the planktonic group at P < 0.05.

Abbreviation: MIC, minimum inhibitory concentration.

LPSs of the P. aeruginosa cell membrane also have an essential barrier function and directly affect bacterial susceptibility for antibiotics.24 We therefore analyzed the LPS profile by SDS–PAGE and silver stain. LPSs displayed a ladder-like pattern of bands with the slower migrating band of the LPS extract in the O-antigen region and the faster band in the lipid A region (Figure 1). In comparison to planktonic cells, biofilm-forming cells showed a different LPS profile; the faster migrating band (lipid A) had an increased staining intensity and a slightly decreased number of bands in the O-antigen region. In the presence of (1/8) MIC of ceftazidime, the number of bands in the O-antigen region increased and the faster migrating band (lipid A) decreased to being barely observable when compared with the control biofilm. For (1/4) MIC of ciprofloxacin and (1/8) MIC of amikacin, the number of bands in the O-antigen region decreased slightly and lipid A intensity increased.
Figure 1

Electrophoretic profile of LPS of Pseudomonas aeruginosa.

Notes: Lane 1, LPS extracted from biofilm cells; lane 2, LPS extracted from planktonic cells; lane 3, LPS extracted from biofilm cells treated with (1/8) MIC of ceftazidime; lane 4, LPS extracted from biofilm cells treated with (1/4) MIC of ciprofloxacin; lane 5, LPS extracted from biofilm cells treated with (1/8) MIC of amikacin.

Abbreviations: LPS, lipopolysaccharide; MIC, minimum inhibitory concentration.

Discussion

Biofilm forms of bacteria are responsible for a variety of life-threatening infections. They have the ability to resist attack by host defenses and show resistance to most antibiotics.25,26 A wide range of pathogens, such as P. aeruginosa and S. aureus, are capable of forming biofilms. Both bacterial types are medically significant microbes and can cause implant and prosthetic device infections. Thus, assessment of possible mechanisms for antibiotic resistance in their biofilm form is critical. Results of this study showed that proteolytic activity increases when bacteria switch from a planktonic to biofilm phenotype. This indicates that biofilms are more virulent and have a greater ability to cause tissue destruction, which correlates with the conclusions of previous studies.27–29 Additionally, the proteolytic potential slightly increased when biofilms were exposed to sublethal concentrations of selected antibiotics. This possibly explains results of clinical studies that show increased severity of disease when subtherapeutic doses or inadequate duration of antibiotics are used.30–33 LPSs are a major constituent of the P. aeruginosa membrane, and changes observed in membrane structure may result in changes to the antibiotic permeability barrier.34,35 For example, the presence of full-length O-antigen renders the LPS smooth, whereas absence or reduction of O-antigen makes the LPS rough. This represents a bacterial shift from an acute to chronic lifestyle, leading to increased persistence of bacteria and a consequent high relapse of disease.36 Results of our study showed decreased O-antigen and increased lipid A in biofilm-forming cells compared to planktonic cells, indicating a phenotypic switch in the LPSs from a smooth form to a rough form.37 Apart from an LPS role in resistance, LPSs are generally considered endotoxins.38 Accordingly, the increased virulence of P. aeruginosa biofilms compared to the planktonic form could be related to an increase in lipid A. In the LPS pattern of P. aeruginosa-treated biofilms, lipid A expression in biofilms exposed to amikacin and ciprofloxacin was up-regulated compared to untreated biofilms. These changes in LPS expression indicate that antibiotic-exposed biofilms had more virulence potential than untreated biofilms. Further studies are required to elucidate the mechanisms by which these antibiotics induce changes in LPSs. In this study we investigated the effect of certain antibiotics on proteolytic activity of P. aeruginosa and S. aureus and/or membrane LPSs of P. aeruginosa. We chose antibiotics that are most commonly used for the treatment of infections by these two bacterial strains. Future work could cover other important antibiotics and also commonly used antibiotics, such as vancomycin and aztreonam. Studies should also address the possibility of membrane protein involvement in increased virulence of biofilms, especially when challenged with sublethal concentrations of antibiotics. Collectively, the antibiotic susceptibility results presented in this study showed that biofilms are more tolerant to antimicrobial agents than planktonic forms. Biofilms (control and treated strains) revealed changes in proteolytic activity and LPS patterns that may result in antibiotic resistance. A decrease in O-antigen bands of LPSs could be a mechanism that helps biofilms evade the immune system, while increased lipid A contents may indicate an increase in biofilm endotoxicity. These LPS changes along with increased protease activity indicate that biofilms are more virulent than their planktonic counterparts. Minimum inhibitory concentration values of Staphylococcus aureus planktonic and biofilm cells Minimum inhibitory concentration values of Pseudomonas aeruginosa planktonic and biofilm cells
Table S1

Minimum inhibitory concentration values of Staphylococcus aureus planktonic and biofilm cells

AntibioticsPlanktonic cellsBiofilm cells
Ciprofloxacin0.5 ± 0.1 μg/mL128 ± 25 μg/mL
Amoxicillin4 ± 0.9 μg/mL512 ± 110 μg/mL
Cotrimoxazole4 ± 0.0 μg/mL256 ± 60 μg/mL
Cefaclor8 ± 1.8 μg/mL>1024 μg/mL
Table S2

Minimum inhibitory concentration values of Pseudomonas aeruginosa planktonic and biofilm cells

AntibioticsPlanktonic cellsBiofilm cells
Ciprofloxacin0.125 ± 0.02 μg/mL64 ± 13 μg/mL
Ceftazidime2 ± 0.4 μg/mL256 ± 80 μg/mL
Cotrimoxazole256 ± 60 μg/mL512 ± 100 μg/mL
Amikacin2 ± 0.0 μg/mL0.02 ± 0.004 μg/mL
  37 in total

Review 1.  Microbial biofilms: from ecology to molecular genetics.

Authors:  M E Davey; G A O'toole
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

2.  Activation of human matrix metalloproteinases by various bacterial proteinases.

Authors:  T Okamoto; T Akaike; M Suga; S Tanase; H Horie; S Miyajima; M Ando; Y Ichinose; H Maeda
Journal:  J Biol Chem       Date:  1997-02-28       Impact factor: 5.157

Review 3.  Staphylococcal biofilms: quest for the magic bullet.

Authors:  Jamie L Brooks; Kimberly K Jefferson
Journal:  Adv Appl Microbiol       Date:  2012       Impact factor: 5.086

Review 4.  Macrolide antibiotics: binding site, mechanism of action, resistance.

Authors:  Marne Gaynor; Alexander S Mankin
Journal:  Curr Top Med Chem       Date:  2003       Impact factor: 3.295

5.  Adherence of coagulase-negative staphylococci to plastic tissue culture plates: a quantitative model for the adherence of staphylococci to medical devices.

Authors:  G D Christensen; W A Simpson; J J Younger; L M Baddour; F F Barrett; D M Melton; E H Beachey
Journal:  J Clin Microbiol       Date:  1985-12       Impact factor: 5.948

6.  A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels.

Authors:  C M Tsai; C E Frasch
Journal:  Anal Biochem       Date:  1982-01-01       Impact factor: 3.365

7.  Differential proteinase expression by Pseudomonas aeruginosa derived from chronic leg ulcers.

Authors:  A Schmidtchen; H Wolff; C Hansson
Journal:  Acta Derm Venereol       Date:  2001 Nov-Dec       Impact factor: 4.437

8.  Effect of subinhibitory concentrations of vancomycin, cefazolin, ofloxacin, L-ofloxacin and D-ofloxacin on adherence to intravascular catheters and biofilm formation by Staphylococcus epidermidis.

Authors:  M E Rupp; K E Hamer
Journal:  J Antimicrob Chemother       Date:  1998-02       Impact factor: 5.790

9.  Resistant strains of Pseudomonas aeruginosa isolated after exposure to several beta-lactam antibiotics.

Authors:  J L Hoekstra; A J de Neeling; V van Klingeren; E E Stobberingh; C P van Boven
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

10.  Lipopolysaccharide heterogeneity among Burkholderia pseudomallei from different geographic and clinical origins.

Authors:  Narisara Anuntagool; Vanaporn Wuthiekanun; Nicholas J White; Bart J Currie; Rasana W Sermswan; Surasakdi Wongratanacheewin; Suwimol Taweechaisupapong; Sansanee C Chaiyaroj; Stitaya Sirisinha
Journal:  Am J Trop Med Hyg       Date:  2006-03       Impact factor: 2.345

View more
  10 in total

1.  Cerium oxide and iron oxide nanoparticles abolish the antibacterial activity of ciprofloxacin against gram positive and gram negative biofilm bacteria.

Authors:  Majed M Masadeh; Ghadah A Karasneh; Mohammad A Al-Akhras; Borhan A Albiss; Khaled M Aljarah; Sayer I Al-Azzam; Karem H Alzoubi
Journal:  Cytotechnology       Date:  2014-03-19       Impact factor: 2.058

2.  Efficacy of combined vancomycin and fosfomycin against methicillin-resistant Staphylococcus aureus in biofilms in vivo.

Authors:  Jian Shi; Ning-Fang Mao; Li Wang; Han-Bo Zhang; Qian Chen; Hua Liu; Xun Tang; Tao Jin; Chong-Tao Zhu; Fu-Bing Li; Lin-Hui Sun; Xin-Ming Xu; Yong-Qing Xu
Journal:  PLoS One       Date:  2014-12-31       Impact factor: 3.240

3.  Defeating Bacterial Resistance and Preventing Mammalian Cells Toxicity Through Rational Design of Antibiotic-Functionalized Nanoparticles.

Authors:  Jessica Fernanda Affonso de Oliveira; Ângela Saito; Ariadne Tuckmantel Bido; Jörg Kobarg; Hubert Karl Stassen; Mateus Borba Cardoso
Journal:  Sci Rep       Date:  2017-05-02       Impact factor: 4.379

4.  Identification of Anti-staphylococcal and Anti-biofilm Compounds by Repurposing the Medicines for Malaria Venture Pathogen Box.

Authors:  Vasundhra Bhandari; Shalini Chakraborty; Umarani Brahma; Paresh Sharma
Journal:  Front Cell Infect Microbiol       Date:  2018-10-23       Impact factor: 5.293

5.  Bioactive glass S53P4 eradicates Staphylococcus aureus in biofilm/planktonic states in vitro.

Authors:  Torstein Grønseth; Lene K Vestby; Live L Nesse; Magnus von Unge; Juha T Silvola
Journal:  Ups J Med Sci       Date:  2020-06-18       Impact factor: 2.384

6.  Sub-MIC of antibiotics induced biofilm formation of Pseudomonas aeruginosa in the presence of chlorhexidine.

Authors:  Safaa T Aka; Sayran H Haji
Journal:  Braz J Microbiol       Date:  2015-03-01       Impact factor: 2.476

7.  Optimization and Evaluation of a Chitosan/Hydroxypropyl Methylcellulose Hydrogel Containing Toluidine Blue O for Antimicrobial Photodynamic Inactivation.

Authors:  Chueh-Pin Chen; Chien-Ming Hsieh; Tsuimin Tsai; Jen-Chang Yang; Chin-Tin Chen
Journal:  Int J Mol Sci       Date:  2015-09-01       Impact factor: 5.923

8.  Changes in the lipopolysaccharide of Proteus mirabilis 9B-m (O11a) clinical strain in response to planktonic or biofilm type of growth.

Authors:  Agnieszka Zabłotni; Dominik Matusiak; Nikolay P Arbatsky; Magdalena Moryl; Anna Maciejewska; Anna N Kondakova; Alexander S Shashkov; Czesław Ługowski; Yuriy A Knirel; Antoni Różalski
Journal:  Med Microbiol Immunol       Date:  2018-01-12       Impact factor: 3.402

9.  Drug resistance of oral bacteria to new antibacterial dental monomer dimethylaminohexadecyl methacrylate.

Authors:  Suping Wang; Haohao Wang; Biao Ren; Xiaodong Li; Lin Wang; Han Zhou; Michael D Weir; Xuedong Zhou; Radi M Masri; Thomas W Oates; Lei Cheng; Hockin H K Xu
Journal:  Sci Rep       Date:  2018-04-03       Impact factor: 4.379

10.  In Vitro Comparison of Antibacterial and Antibiofilm Activities of Selected Fluoroquinolones against Pseudomonas aeruginosa and Methicillin-Resistant Staphylococcus aureus.

Authors:  Majed M Masadeh; Karem H Alzoubi; Wesam S Ahmed; Aisha S Magaji
Journal:  Pathogens       Date:  2019-01-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.